Deal Details

Alumis Completes $345.1 Million Follow-On Offering

Healthcare

Alumis follow-on offering

Summary

Alumis Inc. (“Alumis”) (NASDAQ: ALMS), recently completed an upsized underwritten public offering (the “Offering”) of 20,297,500 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares of common stock, at a price of $17.00 per share, generating gross proceeds of approximately $345.1 million.

Baird served as a lead manager on this Offering.

About

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib (or envu, formerly known as ESK-001) for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. Alumis is headquartered in South San Francisco, California.

Healthcare

Alumis follow-on offering